
Neotiv GmbH closes €10m seed financing
In light of the high-profile Phase III Clarity trial results of Esai/Biogen's Alzheimer's protofibril inhibitor lecanemab, early diagnosis of...

Evidence of deliberate climate damage
For decades, some members of the fossil fuel industry tried to convince the public that a causative link between fossil fuel use and climate warming...

First allogeneic cancer immunotherapy hits market
On December 20th, the European Commission approved Tabelecleucel (EbvalloTM) as a monotherapy for the treatment of adult and paediatric patients who...

Hummingbird and Synaffix in $150m ADC deal
Under the deal, Synaffix can earn up to $150m, including upfront and milestone payments, plus royalties on net sales if the ADC resulting from the...

Evonetix extends Series B financing to US$54m
According to Evonetix Ltd, a benchtop gene synthesis specialist, the investment, which also includes existing investors such as Molten Ventures,...

ExeVir receives EIB risk finance for multiple COVID-19 nanobody
With the resurgence of COVID-19 in China, ExeVir BIO sees commercial potential in the future treatment of immunocompromised people, who make up 3%...

SOTIO licences first cancer ADC from LegoChem Biosciences
The announcement of Czech immuno-oncology specialist SOTIO AS reported came along with promising safety and efficacy Phase I results of LegoChem...